Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

NCT02988843 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Funding Unavailable

Conditions

Germ Cell Tumor

Interventions

DRUG: Brentuximab Vedotin
DRUG: Bevacizumab

Sponsor

Masonic Cancer Center, University of Minnesota